2765 completed, 875 terminated, 846 recruiting, 642 unknown. 6202 Phase 2, 1631 Phase 1, 167 Phase 3.
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Excyte Biopharma Ltd | 64 | 2027-12-01 | 2026-11-06 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-04-29 | 2026-11-05 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
Showing 20 of 6202. Sign in to see all of them.
Multiple Myeloma (1583) · Lymphoma (1276) · Lymphoma, Non-Hodgkin (1002) · Leukemia, Lymphocytic, Chronic, B-Cell (920) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (899) · Lymphoma, Large B-Cell, Diffuse (874) · Lymphoma, Follicular (719) · Leukemia (627) · Lymphoma, Mantle-Cell (604) · Hodgkin Disease (590) · Recurrence (581) · Leukemia, Myeloid, Acute (440) · Burkitt Lymphoma (419) · Lymphoma, B-Cell, Marginal Zone (393) · Myelodysplastic Syndromes (348)
Immune System Diseases (6163) · Hemic and Lymphatic Diseases (6142) · Immunoproliferative Disorders (6099) · Neoplasms by Histologic Type (6047) · Neoplasms (5881) · Lymphatic Diseases (4867) · Hematologic Diseases (3458) · Lymphoma (2358) · Lymphoma, Non-Hodgkin (1891) · Paraproteinemias (1811) · Cardiovascular Diseases (1807) · Vascular Diseases (1799) · Hemorrhagic Disorders (1781) · Blood Protein Disorders (1774)
Cyclophosphamide (958) · Rituximab (904) · Dexamethasone (739) · Lenalidomide (499) · Bortezomib (396) · Vincristine (388) · Doxorubicin (367) · Etoposide (361) · Prednisone (342) · Cytarabine (310) · Melphalan (302) · fludarabine (288) · Methotrexate (282) · Filgrastim (279) · fludarabine phosphate (272)
M.D. Anderson Cancer Center (312) · National Cancer Institute (NCI) (303) · Memorial Sloan Kettering Cancer Center (150) · Fred Hutchinson Cancer Center (115) · Mayo Clinic (92) · City of Hope Medical Center (78) · Institute of Hematology & Blood Diseases Hospital, China (70) · Dana-Farber Cancer Institute (64) · Novartis Pharmaceuticals (55) · Celgene (49) · Hoffmann-La Roche (49) · Alliance for Clinical Trials in Oncology (47) · GlaxoSmithKline (47) · Masonic Cancer Center, University of Minnesota (44) · Ruijin Hospital (43)
United States (3654) · China (809) · France (494) · Italy (470) · Germany (428) · Spain (388) · Canada (387) · United Kingdom (374) · Australia (280) · South Korea (230) · Belgium (199) · Netherlands (163) · Poland (161) · Japan (143) · Israel (132)
Elias Jabbour (13)
PMID 41671463, PMID 34515338, PMID 35622074, PMID 32499241, PMID 40135712, PMID 40550489, PMID 31401903, PMID 32632956, PMID 33357481, PMID 39319495, PMID 34398557, PMID 23524640, PMID 27209293, PMID 29358183, PMID 23065508, PMID 23834234, PMID 35285981, PMID 35549810, PMID 38502198, PMID 39563886, PMID 40802906, PMID 17242396, PMID 18596230, PMID 21403127, PMID 22430088, PMID 24443277, PMID 26182309, PMID 26308596, PMID 26373676, PMID 27282998, PMID 30125215, PMID 30620669, PMID 30957581, PMID 31050355, PMID 31221778, PMID 32770353, PMID 33242441, PMID 34048072, PMID 34182226, PMID 34608724, PMID 34780125, PMID 35007144, PMID 35787017, PMID 35882475, PMID 37934000, PMID 37981564, PMID 38551807, PMID 40156952, PMID 40226119, PMID 40472301
2023 (83), P30CA015704 (60), P30CA015083 (56), P30CA033572 (54), 2017 (44), 2015 (43), U10CA180820 (43), 2018 (41), U10CA032102 (38), 2016 (35), 2025 (35), 2014 (34), U10CA031946 (34), 2009 (29), P30CA016672 (28)